Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
Τίτλος | Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. |
Publication Type | Journal Article |
Year of Publication | 2008 |
Authors | Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Koukoulis G., Kita M., & Avramidis A. |
Journal | Horm Metab Res |
Volume | 40 |
Issue | 4 |
Pagination | 281-5 |
Date Published | 2008 Apr |
ISSN | 0018-5043 |
Λέξεις κλειδιά | Aged, Biomarkers, Bone Density Conservation Agents, Calcium, Collagen Type I, Etidronic Acid, Female, Humans, Middle Aged, Osteoporosis, Postmenopausal, Osteoprotegerin, RANK Ligand, Risedronic Acid, Teriparatide |
Abstract | Risedronate and teriparatide have opposite actions on the osteoblast-osteoclast dipole and are expected to influence the RANK/RANKL/osteoprotegerin (OPG) system. We aimed to evaluate changes in serum OPG and RANKL after risedronate or teriparatide administration in postmenopausal osteoporotic women. Seventy-four postmenopausal Caucasian women (age 64.1+/-1.0 years) were studied. Women with osteopenia served as controls (group 1, n=30). Women with osteoporosis were randomly assigned to either risedronate 35 mg once weekly (group 2, n=21) or teriparatide 20 microg once daily (group 3, n=23) for six months. Blood samples for serum RANKL, OPG, N-terminal propeptide of type 1 collagen (P1NP), and C-terminal telopeptide of type 1 collagen (CTx) were obtained before treatment and three and six months after treatment. P1NP and CTx levels remained unchanged in group 1, decreased in group 2 (p<0.001), and increased in group 3 women (p<0.001) throughout the treatment. OPG levels remained unchanged while RANKL decreased gradually in all groups (p<0.001). There was no correlation between OPG or RANKL and P1NP or CTx. Our data suggest that neither antiresorptive nor osteoanabolic therapy causes specific alterations of serum OPG/RANKL levels; therefore, these cytokines cannot substitute for the established markers of bone turnover in the monitoring of response to osteoporosis treatment. |
DOI | 10.1055/s-2008-1046787 |
Alternate Journal | Horm. Metab. Res. |
PubMed ID | 18275008 |